このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Champions Oncology 配当金

配当金基準チェック /06

Champions Oncology配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	0.4%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.72
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04

決済の安定と成長

配当データの取得

安定した配当: CSBRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: CSBRの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Champions Oncology 配当利回り対市場

CSBR 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (CSBR)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Life Sciences)	0.4%
3年後のアナリスト予想 (CSBR)	n/a

注目すべき配当: CSBRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: CSBRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: CSBRの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: CSBRが配当金を報告していないため、配当金の持続可能性を計算できません。

Champions Oncology 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023)

Champions Oncology, Inc. to Report Q3, 2024 Results on Mar 12, 2024

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Champions Oncology, Inc. to Report Q2, 2024 Results on Dec 12, 2023

Champions Oncology, Inc. Appoints Brady Davis as President

Independent Director recently bought US$97k worth of stock

Consensus EPS estimates upgraded to US$0.49 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Champions Oncology, Inc. to Report Q1, 2024 Results on Sep 13, 2023

Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Champions Oncology, Inc. to Report Q4, 2023 Results on Jul 24, 2023

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 33%

Consensus EPS estimates have been downgraded.

Price target decreased to US$13.67

Champions Oncology, Inc. to Report Q2, 2023 Results on Dec 13, 2022

Insufficient new directors

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Consensus EPS estimates increase by 100%

Champions Oncology, Inc. to Report Q1, 2023 Results on Sep 08, 2022

Champions Oncology, Inc., Annual General Meeting, Oct 20, 2022

Consensus forecasts updated

Full year 2022 earnings released: EPS: US$0.042 (vs US$0.028 in FY 2021)

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.006 profit in 1Q 2021)

Full year 2021 earnings released: EPS US$0.025 (vs US$0.17 loss in FY 2020)

Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell 2500 Growth Index

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Price target increased to US$15.00

Revenue and earnings beat expectations

Third quarter 2021 earnings released: EPS US$0.055 (vs US$0.035 in 3Q 2020)

New 90-day high: US$12.21

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Independent Director has left the company

Champions Oncology, Inc. Announces Resignation of Abba David Poliakoff as Board of Director

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Board Member recently sold US$357k worth of stock

Price target raised to US$12.83

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology, Inc. Revises Revenue Guidance for the Year 2021

Champions Oncology beats on revenue

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

New 90-day high: US$9.99

Champions Oncology, Inc. to Report Q1, 2021 Results on Sep 14, 2020

First quarter earnings released

New 90-day low - US$7.05

New 90-day low - US$8.28

New 90-day high - US$9.96

Champions Oncology, Inc.(NasdaqCM:CSBR) dropped from Russell Microcap Value Index

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06